Cargando…

The Progression of Cell Death Affects the Rejection of Allogeneic Tumors in Immune-Competent Mice – Implications for Cancer Therapy

Large amounts of dead and dying cells are produced during cancer therapy and allograft rejection. Depending on the death pathway and stimuli involved, dying cells exhibit diverse features, resulting in defined physiological consequences for the host. It is not fully understood how dying and dead cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Chaurio, Ricardo A., Muñoz, Luis E., Maueröder, Christian, Janko, Christina, Harrer, Thomas, Fürnrohr, Barbara G., Niederweis, Michael, Bilyy, Rostyslav, Schett, Georg, Herrmann, Martin, Berens, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4227513/
https://www.ncbi.nlm.nih.gov/pubmed/25426116
http://dx.doi.org/10.3389/fimmu.2014.00560
_version_ 1782343820900302848
author Chaurio, Ricardo A.
Muñoz, Luis E.
Maueröder, Christian
Janko, Christina
Harrer, Thomas
Fürnrohr, Barbara G.
Niederweis, Michael
Bilyy, Rostyslav
Schett, Georg
Herrmann, Martin
Berens, Christian
author_facet Chaurio, Ricardo A.
Muñoz, Luis E.
Maueröder, Christian
Janko, Christina
Harrer, Thomas
Fürnrohr, Barbara G.
Niederweis, Michael
Bilyy, Rostyslav
Schett, Georg
Herrmann, Martin
Berens, Christian
author_sort Chaurio, Ricardo A.
collection PubMed
description Large amounts of dead and dying cells are produced during cancer therapy and allograft rejection. Depending on the death pathway and stimuli involved, dying cells exhibit diverse features, resulting in defined physiological consequences for the host. It is not fully understood how dying and dead cells modulate the immune response of the host. To address this problem, different death stimuli were studied in B16F10 melanoma cells by regulated inducible transgene expression of the pro-apoptotic active forms of caspase-3 (revCasp-3), Bid (tBid), and the Mycobacterium tuberculosis-necrosis inducing toxin (CpnT(CTD)). The immune outcome elicited for each death stimulus was assessed by evaluating the allograft rejection of melanoma tumors implanted subcutaneously in BALB/c mice immunized with dying cells. Expression of all proteins efficiently killed cells in vitro (>90%) and displayed distinctive morphological and physiological features as assessed by multiparametric flow cytometry analysis. BALB/c mice immunized with allogeneic dying melanoma cells expressing revCasp-3 or CpnT(CTD) showed strong rejection of the allogeneic challenge. In contrast, mice immunized with cells dying either after expression of tBid or irradiation with UVB did not, suggesting an immunologically silent cell death. Surprisingly, immunogenic cell death induced by expression of revCasp-3 or CpnT(CTD) correlated with elevated intracellular reactive oxygen species (ROS) levels at the time point of immunization. Conversely, early mitochondrial dysfunction induced by tBid expression or UVB irradiation accounted for the absence of intracellular ROS accumulation at the time point of immunization. Although ROS inhibition in vitro was not sufficient to abrogate the immunogenicity in our allo-immunization model, we suggest that the point of ROS generation and its intracellular accumulation may be an important factor for its role as damage associated molecular pattern in the development of allogeneic responses.
format Online
Article
Text
id pubmed-4227513
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-42275132014-11-25 The Progression of Cell Death Affects the Rejection of Allogeneic Tumors in Immune-Competent Mice – Implications for Cancer Therapy Chaurio, Ricardo A. Muñoz, Luis E. Maueröder, Christian Janko, Christina Harrer, Thomas Fürnrohr, Barbara G. Niederweis, Michael Bilyy, Rostyslav Schett, Georg Herrmann, Martin Berens, Christian Front Immunol Immunology Large amounts of dead and dying cells are produced during cancer therapy and allograft rejection. Depending on the death pathway and stimuli involved, dying cells exhibit diverse features, resulting in defined physiological consequences for the host. It is not fully understood how dying and dead cells modulate the immune response of the host. To address this problem, different death stimuli were studied in B16F10 melanoma cells by regulated inducible transgene expression of the pro-apoptotic active forms of caspase-3 (revCasp-3), Bid (tBid), and the Mycobacterium tuberculosis-necrosis inducing toxin (CpnT(CTD)). The immune outcome elicited for each death stimulus was assessed by evaluating the allograft rejection of melanoma tumors implanted subcutaneously in BALB/c mice immunized with dying cells. Expression of all proteins efficiently killed cells in vitro (>90%) and displayed distinctive morphological and physiological features as assessed by multiparametric flow cytometry analysis. BALB/c mice immunized with allogeneic dying melanoma cells expressing revCasp-3 or CpnT(CTD) showed strong rejection of the allogeneic challenge. In contrast, mice immunized with cells dying either after expression of tBid or irradiation with UVB did not, suggesting an immunologically silent cell death. Surprisingly, immunogenic cell death induced by expression of revCasp-3 or CpnT(CTD) correlated with elevated intracellular reactive oxygen species (ROS) levels at the time point of immunization. Conversely, early mitochondrial dysfunction induced by tBid expression or UVB irradiation accounted for the absence of intracellular ROS accumulation at the time point of immunization. Although ROS inhibition in vitro was not sufficient to abrogate the immunogenicity in our allo-immunization model, we suggest that the point of ROS generation and its intracellular accumulation may be an important factor for its role as damage associated molecular pattern in the development of allogeneic responses. Frontiers Media S.A. 2014-11-11 /pmc/articles/PMC4227513/ /pubmed/25426116 http://dx.doi.org/10.3389/fimmu.2014.00560 Text en Copyright © 2014 Chaurio, Muñoz, Maueröder, Janko, Harrer, Fürnrohr, Niederweis, Bilyy, Schett, Herrmann and Berens. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Chaurio, Ricardo A.
Muñoz, Luis E.
Maueröder, Christian
Janko, Christina
Harrer, Thomas
Fürnrohr, Barbara G.
Niederweis, Michael
Bilyy, Rostyslav
Schett, Georg
Herrmann, Martin
Berens, Christian
The Progression of Cell Death Affects the Rejection of Allogeneic Tumors in Immune-Competent Mice – Implications for Cancer Therapy
title The Progression of Cell Death Affects the Rejection of Allogeneic Tumors in Immune-Competent Mice – Implications for Cancer Therapy
title_full The Progression of Cell Death Affects the Rejection of Allogeneic Tumors in Immune-Competent Mice – Implications for Cancer Therapy
title_fullStr The Progression of Cell Death Affects the Rejection of Allogeneic Tumors in Immune-Competent Mice – Implications for Cancer Therapy
title_full_unstemmed The Progression of Cell Death Affects the Rejection of Allogeneic Tumors in Immune-Competent Mice – Implications for Cancer Therapy
title_short The Progression of Cell Death Affects the Rejection of Allogeneic Tumors in Immune-Competent Mice – Implications for Cancer Therapy
title_sort progression of cell death affects the rejection of allogeneic tumors in immune-competent mice – implications for cancer therapy
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4227513/
https://www.ncbi.nlm.nih.gov/pubmed/25426116
http://dx.doi.org/10.3389/fimmu.2014.00560
work_keys_str_mv AT chaurioricardoa theprogressionofcelldeathaffectstherejectionofallogeneictumorsinimmunecompetentmiceimplicationsforcancertherapy
AT munozluise theprogressionofcelldeathaffectstherejectionofallogeneictumorsinimmunecompetentmiceimplicationsforcancertherapy
AT maueroderchristian theprogressionofcelldeathaffectstherejectionofallogeneictumorsinimmunecompetentmiceimplicationsforcancertherapy
AT jankochristina theprogressionofcelldeathaffectstherejectionofallogeneictumorsinimmunecompetentmiceimplicationsforcancertherapy
AT harrerthomas theprogressionofcelldeathaffectstherejectionofallogeneictumorsinimmunecompetentmiceimplicationsforcancertherapy
AT furnrohrbarbarag theprogressionofcelldeathaffectstherejectionofallogeneictumorsinimmunecompetentmiceimplicationsforcancertherapy
AT niederweismichael theprogressionofcelldeathaffectstherejectionofallogeneictumorsinimmunecompetentmiceimplicationsforcancertherapy
AT bilyyrostyslav theprogressionofcelldeathaffectstherejectionofallogeneictumorsinimmunecompetentmiceimplicationsforcancertherapy
AT schettgeorg theprogressionofcelldeathaffectstherejectionofallogeneictumorsinimmunecompetentmiceimplicationsforcancertherapy
AT herrmannmartin theprogressionofcelldeathaffectstherejectionofallogeneictumorsinimmunecompetentmiceimplicationsforcancertherapy
AT berenschristian theprogressionofcelldeathaffectstherejectionofallogeneictumorsinimmunecompetentmiceimplicationsforcancertherapy
AT chaurioricardoa progressionofcelldeathaffectstherejectionofallogeneictumorsinimmunecompetentmiceimplicationsforcancertherapy
AT munozluise progressionofcelldeathaffectstherejectionofallogeneictumorsinimmunecompetentmiceimplicationsforcancertherapy
AT maueroderchristian progressionofcelldeathaffectstherejectionofallogeneictumorsinimmunecompetentmiceimplicationsforcancertherapy
AT jankochristina progressionofcelldeathaffectstherejectionofallogeneictumorsinimmunecompetentmiceimplicationsforcancertherapy
AT harrerthomas progressionofcelldeathaffectstherejectionofallogeneictumorsinimmunecompetentmiceimplicationsforcancertherapy
AT furnrohrbarbarag progressionofcelldeathaffectstherejectionofallogeneictumorsinimmunecompetentmiceimplicationsforcancertherapy
AT niederweismichael progressionofcelldeathaffectstherejectionofallogeneictumorsinimmunecompetentmiceimplicationsforcancertherapy
AT bilyyrostyslav progressionofcelldeathaffectstherejectionofallogeneictumorsinimmunecompetentmiceimplicationsforcancertherapy
AT schettgeorg progressionofcelldeathaffectstherejectionofallogeneictumorsinimmunecompetentmiceimplicationsforcancertherapy
AT herrmannmartin progressionofcelldeathaffectstherejectionofallogeneictumorsinimmunecompetentmiceimplicationsforcancertherapy
AT berenschristian progressionofcelldeathaffectstherejectionofallogeneictumorsinimmunecompetentmiceimplicationsforcancertherapy